X

JAMA Network

JAMA Network
Association Between Measurable Residual Disease in Patients With Intermediate-Risk AML and First Remission, Treatment, and Outcomes

This study suggests that clinical decisions based on dynamic measurable residual disease might be associated with improved therapy stratification and optimized postremission treatment for patients

JAMA Network
07/07/2021
CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma

Lisocabtagene maraleucel, marketed as Breyanzi, is a CAR-T therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.

JAMA Network
03/16/2021
CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma

Lisocabtagene maraleucel is a CAR-T therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.

JAMA Network
03/16/2021
Subscribe to JAMA Network

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
#575662
#a60538
#49cde9
#c20fce
#d95d39
#eb5834